330 related articles for article (PubMed ID: 9157585)
1. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
Fijnvandraat K; Berntorp E; ten Cate JW; Johnsson H; Peters M; Savidge G; Tengborn L; Spira J; Stahl C
Thromb Haemost; 1997 Feb; 77(2):298-302. PubMed ID: 9157585
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
Rea C; Dunkerley A; Sørensen B; Rangarajan S
Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
[TBL] [Abstract][Full Text] [Related]
3. Second generation, B-domain deleted recombinant factor VIII.
Berntorp E
Thromb Haemost; 1997 Jul; 78(1):256-60. PubMed ID: 9198162
[TBL] [Abstract][Full Text] [Related]
4. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.
Powell JS; Nugent DJ; Harrison JA; Soni A; Luk A; Stass H; Gorina E
J Thromb Haemost; 2008 Feb; 6(2):277-83. PubMed ID: 18039351
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.
Kempton CL; Abshire TC; Deveras RA; Hoots WK; Gill JC; Kessler CM; Key NS; Konkle BA; Kuriakose P; Macfarlane DE; Bergman G
Haemophilia; 2012 Sep; 18(5):798-804. PubMed ID: 22512291
[TBL] [Abstract][Full Text] [Related]
6. The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII?
Johnston A
Ther Drug Monit; 2012 Feb; 34(1):110-7. PubMed ID: 22249347
[TBL] [Abstract][Full Text] [Related]
7. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII).
Santoro C; Iorio A; Ferrante F; Pallotta A; Pignoloni P; Biondo F; Agnelli G; Mazzucconi MG
Haemophilia; 2009 May; 15(3):779-87. PubMed ID: 19298379
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). The Recombinate Study Group.
Morfini M; Longo G; Messori A; Lee M; White G; Mannucci P
Thromb Haemost; 1992 Oct; 68(4):433-5. PubMed ID: 1448776
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG
Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768
[TBL] [Abstract][Full Text] [Related]
10. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
[TBL] [Abstract][Full Text] [Related]
11. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
Deitcher SR; Tuller J; Johnson JA
Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.
Fukui H; Yoshioka A; Shima M; Tanaka I; Koshihara K; Fukutake K; Fujimaki M
Int J Hematol; 1991 Oct; 54(5):419-27. PubMed ID: 1756252
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
[TBL] [Abstract][Full Text] [Related]
14. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
[TBL] [Abstract][Full Text] [Related]
15. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
[TBL] [Abstract][Full Text] [Related]
16. Thrombomodulin-modified thrombin generation after in vivo recombinant factor VIII treatment in severe hemophilia A.
Dielis AW; Balliël WM; van Oerle R; Hermens WT; Spronk HM; Ten Cate H; Hamulyák K
Haematologica; 2008 Sep; 93(9):1351-7. PubMed ID: 18641016
[TBL] [Abstract][Full Text] [Related]
17. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A.
Dmoszynska A; Hellmann A; Baglin T; O'Shaugnessy D; Trelinski J; Kuliczkowski K; Kloczko J; Hay C; Zawilska K; Makris M; Shaikh-Zaidi R; Gascoigne E; Dash C
Haemophilia; 2011 Mar; 17(2):185-90. PubMed ID: 21070496
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
Zhang Y; Roberts J; Tortorici M; Veldman A; St Ledger K; Feussner A; Sidhu J
J Thromb Haemost; 2017 Jun; 15(6):1106-1114. PubMed ID: 28244200
[TBL] [Abstract][Full Text] [Related]
20. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.
Powell JS; Josephson NC; Quon D; Ragni MV; Cheng G; Li E; Jiang H; Li L; Dumont JA; Goyal J; Zhang X; Sommer J; McCue J; Barbetti M; Luk A; Pierce GF
Blood; 2012 Mar; 119(13):3031-7. PubMed ID: 22223821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
